There is no single "how long does Juvederm Ultra last" figure, because the FDA record contains two separate trials answering two separate questions: One tested the lips. One tested nasolabial folds. They ran for different lengths of time, used different rating scales and produced different results. Merging them gives a number that belongs to neither.
Both products sit under PMA P050047, originally approved 2 June 2006, with the lidocaine-containing versions approved on 7 January 2010.
Juvederm Ultra XC gained its lip and perioral indication on 30 September 2015, on the basis of a prospective, randomised, multicentre trial run across 9 US sites, with evaluators blinded and a delayed-treatment (no-treatment) control group: People were randomised 3 to 1, giving an analysis set of 213 — 157 treated and 56 control. Controls crossed over to treatment at 3 months. Enrolment ran from August 2010 to December 2013.
A responder was someone rated at least one point better than their own baseline on the manufacturer's validated lip fullness scale.
Month 3, the primary timepoint — 79.1 percent of treated people were responders, against 26.1 percent of controls: (p less than 0.0001, against a pre-specified threshold of 60 percent)
Month 6 — 80.5 percent
Month 12 — 56.4 percent
The follow-up window was 12 months: That is why "up to a year" is the phrase attached to lip filler with this product — it is the edge of the study, not a measured endpoint of the effect.
And the month-12 figure is the one worth sitting with. At the last measured visit, roughly 44 percent of treated people no longer met even a one-grade improvement in lip fullness: "Up to a year" describes the best case at the outer edge of the window. It does not describe the average experience.
The wrinkles-and-folds indication that both Ultra XC and Ultra Plus XC hold rests on the original 2006 pivotal trial: prospective, double-blind, randomised, three-armed and within-subject (split-face) controlled, across multiple centres. 439 people were randomised and 423 — 96.4 percent — completed 24 weeks.
Twenty-four weeks, about 6 months, is the entire pivotal window for this indication.
The comparator was a bovine collagen injectable, an approved product and the standard of 2006. Mean nasolabial fold severity as rated by independent reviewers, for the Ultra formulation against that comparator, was 0.6 versus 0.7 at week 2, 0.9 versus 1.6 at week 12, and 1.3 versus 2.3 at week 24. All three formulations met non-inferiority at 12 weeks, and the Ultra and Ultra Plus formulations met superiority against collagen at 24 weeks.
Two things that result does not mean: It does not mean either product outperformed any modern hyaluronic acid filler — the comparator was collagen. And a non-inferiority result, which is what the 12-week analysis was, is a demonstration that a difference larger than a pre-set margin was not found. It is not a win.
Where do the longer durations in marketing come from, then?: A labeling supplement approved on 11 June 2007 was described in the FDA record as approving labeling modifications adding additional follow-up data. That supplement is the origin of longer-duration label language for this line. The pivotal window in the public summary is 24 weeks.
Ultra Plus XC was studied in the same 24-week nasolabial fold pivotal as Ultra XC. It has no separate pivotal with a longer follow-up window in the US approval record, and it holds no US lip indication: Its approved wording covers injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.
The two products contain the same hyaluronic acid concentration and the same lidocaine concentration, and differ in how heavily the gel is cross-linked and in the needle they are supplied with. That difference is set out on the page comparing Ultra and Ultra Plus.
No trial has compared Ultra XC against Ultra Plus XC: Firmer gels are widely assumed to last longer in deeper placements, but that assumption has not been tested between these two products, and there is no published figure to cite for it.
Every number above is a responder rate: the share of people a rater judged to be at least one grade better than their own starting point on a fixed scale.
It is not a measurement of how much gel remains. Someone can stop being a responder while filler is still in place — the change is simply no longer big enough to register a full grade. It is also a judgement rather than a physical measurement, which makes it a softer endpoint than it looks.
And every one of these trials was run and submitted by the manufacturer in support of its own FDA approvals, using the manufacturer's own validated rating scales: That is standard for device approval, and the summaries are public FDA documents. It is not independent research.
Juvederm is a family, not a product: Ultra XC, Ultra Plus XC, Voluma XC, Vollure XC, Volbella XC, Volux XC and Skinvive each went through their own FDA approval, for their own area, on their own trial, with their own follow-up window.
Ultra XC and Ultra Plus XC: Moderate to severe facial wrinkles and folds; Ultra XC additionally lips and perioral area
Voluma XC: Cheeks, chin and temples
Vollure XC: Moderate to severe facial wrinkles and folds
Volbella XC: Lips, perioral lines and under-eye hollows
Volux XC: Jawline definition
Skinvive: Skin smoothness of the cheeks, and neck lines
A duration figure quoted for one of these products says nothing about any of the others. And figures from two separate trials, on different scales with different raters, cannot be set against each other to decide which lasts longer.
Both products come in 1.0 mL syringes, with a 0.55 mL fill in the same syringe body approved on 13 March 2019.
The FDA-approved labeling for Juvederm Ultra XC states that initial treatment of the lips and perioral area typically uses about 2.2 mL in total, with repeat treatment around 1.5 mL. That is more than two syringes for an initial lip treatment, which is worth knowing when duration is discussed alongside a one-syringe price. The "one syringe" convention is a commercial and practical unit, not a dose derived from the pivotal trials.
Ultra XC and Ultra Plus XC are hyaluronic acid gels, so hyaluronidase — an enzyme that splits hyaluronic acid — breaks them down, usually within minutes to hours. That is how an unwanted result is undone, and it is the emergency treatment if filler blocks a blood vessel.
Three caveats. In the US, dissolving filler is an off-label use of hyaluronidase; the Hylenex label lists only fluid administration, drug dispersion and urography. Repeat dosing is normal — published guidance describes staged doses rather than a single bolus for a suspected occlusion. And it is not a reliable rescue for filler-related blindness: in a review of 511 published cases, no treatment was significantly associated with visual improvement.
Fillers made from other materials, such as calcium hydroxylapatite or poly-L-lactic acid, are not affected by hyaluronidase at all.
Which product exactly, and is this area an approved use for it?
Which trial figure applies to that product in that area?
How much are you using today, and what would a full correction take?
What should this look like at 6 months, and at 12?
Do you stock hyaluronidase on site?
Go to an emergency department or call 911 if any of these happen during or after an injection. They can mean filler has entered a blood vessel, and time is measured in hours.
Any change in vision: Blurring, a dark patch, double vision or loss of sight in one eye
Sudden severe pain, or pain out of proportion to the injection
Skin turning white (blanching), then dusky, purple, grey or net-like and mottled
Weakness, drooping, slurred speech, confusion or any other stroke-like symptom
Pain is not a dependable warning on its own. In a survey of experienced injectors reporting their own intravascular injections, pain was mild or absent in 47 percent of events.
Swelling keeps growing after the first few days instead of settling
A lump appears and does not soften over a couple of weeks
Redness spreads outward from the injection site
Tenderness, firmness or swelling appears weeks or months later, which can be a delayed inflammatory reaction or an infection
The filler seems to have moved from where it was placed
The lips or folds look visibly uneven once the initial swelling has gone